Get the Stockscreener App
3.40
2.72%
0.09
After Hours:
3.40
Vigil Neuroscience Inc stock is traded at $3.40, with a volume of 84,301.
It is up +2.72% in the last 24 hours and down -2.30% over the past month.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
See More
Previous Close:
$3.31
Open:
$3.32
24h Volume:
84,301
Relative Volume:
0.18
Market Cap:
$129.65M
Revenue:
-
Net Income/Loss:
$-78.92M
P/E Ratio:
-1.6667
EPS:
-2.04
Net Cash Flow:
$-72.87M
1W Performance:
+9.32%
1M Performance:
-2.30%
6M Performance:
-0.29%
1Y Performance:
-36.92%
1-Day Range:
$3.20
$3.43
1-Week Range:
$3.11
$3.43
52-Week Range:
$2.47
$9.24
Vigil Neuroscience Inc Stock (VIGL) Company Profile
Name
Vigil Neuroscience Inc
Sector
Industry
Phone
857-254-4445
Address
100 FORGE ROAD, WATERTOWN
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-23 | Initiated | Mizuho | Buy |
| Sep-16-22 | Initiated | Wedbush | Outperform |
| Aug-29-22 | Initiated | H.C. Wainwright | Buy |
| Feb-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Initiated | Jefferies | Buy |
| Feb-01-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-01-22 | Initiated | Stifel | Buy |
View All
Vigil Neuroscience Inc Stock (VIGL) Latest News
Ensign Peak Advisors Inc Buys 166,442 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 20.3% in September - MarketBeat
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Certified Advisory Corp Grows Stake in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Shares Purchased by Harmony Asset Management LLC - Defense World
Evergreen Capital Management LLC Sells 380 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Circle Wealth Management LLC Acquires 383 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Garden State Investment Advisory Services LLC Acquires 743 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
VICOR 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Vicor CorporationVICR - Business Wire
INVESTOR DEADLINE MONDAY: Robbins Geller Rudman & Dowd LLP Announces that Vicor Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – VICR - ForexTV.com
Vigil Neuroscience shares maintain Outperform rating on positive FDA update - Investing.com
WCG Wealth Advisors LLC Has $3 Million Position in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Bradley Foster & Sargent Inc. CT Cuts Position in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
1,275 Shares in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Bought by One Capital Management LLC - Defense World
Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Shares Sold by ProVise Management Group LLC - Defense World
Vigil Neuroscience shares maintain Outperform rating on positive FDA update By Investing.com - Investing.com Australia
FDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trial - Clinical Trials Arena
FDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trial - Yahoo Finance
FDA lifts hold on Vigil Neuroscience's Alzheimer trial By Investing.com - Investing.com Canada
FDA lifts hold on Vigil Neuroscience's Alzheimer trial By Investing.com - Investing.com South Africa
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 - ForexTV.com
Vigil stock gains as FDA removes partial hold (NASDAQ:VIGL) - Seeking Alpha
FDA lifts hold on Vigil Neuroscience's Alzheimer trial - Investing.com India
Vigil Neuroscience Advances Alzheimer’s Trial, Eyes 2025 Data - TipRanks
Vigil Neuroscience Says FDA Lifts Partial Hold Alzheimer's-Treatment Trial - MarketWatch
Vigil Neuroscience rises as FDA lifts partial hold on Alzheimer’s disease trial - XM
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 - GlobeNewswire
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 - StockTitan
FDA lifts hold on Vigil Neuroscience's Alzheimer trial - Investing.com
The Neuroscience Market Research Explores 2024: Advancing Brain Research and Therapeutics - WhaTech
Vigil Neuroscience to Present at Cantor Global Healthcare Conference - GlobeNewswire
Vigil Neuroscience to Present at Cantor Global Healthcare Conference - StockTitan
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update - MarketBeat
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 23.7% in August - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Trading 5% Higher - MarketBeat
Neurodegenerative Disorder Therapeutics Market Insights Discussed Regarding Size And Outlook 2024-2033 - WhaTech
A stock that deserves closer examination: Vigil Neuroscience Inc (VIGL) - US Post News
You might want to take a look at Vigil Neuroscience Inc (VIGL) now - SETE News
Vigil Neuroscience to Present at Upcoming September Investor Conferences - GlobeNewswire
Vigil Neuroscience to Present at Upcoming September Investor Conferences - StockTitan
Vanguard Group Inc. Acquires 95,276 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Q3 2024 EPS Estimates for Vigil Neuroscience, Inc. Decreased by Analyst (NASDAQ:VIGL) - MarketBeat
Research Analysts Offer Predictions for Vigil Neuroscience, Inc.’s Q3 2024 Earnings (NASDAQ:VIGL) - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Stock Rating Reaffirmed by HC Wainwright - Defense World
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 20.4% in July - MarketBeat
Vigil Neuroscience stays 'on-track'; Stifel reaffirms buy rating on stock - Investing.com India
Vigil Neuroscience stays 'on-track'; Stifel reaffirms buy rating on stock By Investing.com - Investing.com Canada
Vigil Neuroscience stays 'on-track'; Stifel reaffirms buy rating on stock By Investing.com - Investing.com UK
Vigil Neuroscience (NASDAQ:VIGL) Price Target Cut to $16.00 by Analysts at Guggenheim - Defense World
HC Wainwright Analysts Cut Earnings Estimates for Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
FY2027 EPS Estimates for Vigil Neuroscience, Inc. Reduced by HC Wainwright (NASDAQ:VIGL) - Defense World
Vigil Neuroscience Inc Stock (VIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):